Drug news
Avastin is filed at FDA for treatment of Ovarian Cancer - Genentech/Roche
Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with recurrent platinum-resistant Ovarian Cancer.
The application is supported by results from the AURELIA study which showed Avastin plus chemotherapy reduced the risk of the disease worsening (PFS) by 52% compared to chemotherapy alone.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.